+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07538609

Evaluation of the GORE VIABAHN FORTEGRA Venous Stent for Treatment of Venous Disease in a Post-Approval Study

Led by W.L.Gore & Associates · Updated on 2026-10-26

150

Participants Needed

4

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the GORE4 VIABAHN4 FORTEGRA Venous Stent in a prospective, multicenter, single-arm post-market clinical study involving up to 35 sites in the U.S. The study focuses on patients with venous conditions needing treatment with this stent device. The purpose is to assess its use in real-world settings, monitoring safety and effectiveness in treating venous stenosis, occlusion, thromboses, and ulcers. Participants will receive the GORE4 VIABAHN4 FORTEGRA Venous Stent implanted at a clinical site. The procedure is guided by intraoperative imaging to ensure proper sizing and placement. After hospital discharge, participants return for follow-up visits at 1, 6, 12, 24, and 36 months to monitor the stents performance and any related health events. During the study, participants undergo evaluations including imaging to confirm stent patency and complications, and assessments of adverse events within 30 days and up to 36 months. The primary outcomes include safety events shortly after implantation and effectiveness at maintaining vessel openness after 12 months. Quality of life and technical success of the procedure are also measured. Participants are monitored for up to 3 years, with visits to assess their status and the devices function.

CONDITIONS

Brief Title

The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study

Research Team

C

Chaz Wolf

L

Leonard Resecker

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here